We're trimming a health-care stock into strength and raising our price target

Jim Cramer's Charitable Trust is selling 50 shares of Cardinal Health at roughly $235, cutting the position to 375 shares and lowering portfolio weight to 2.25% from 2.50%. The stock has rallied 6% this week and 20% this month to a new all-time high, prompting the trim after the position moved from a heavy loss to a small gain of about 1%. The trust also raised its price target on CAH to $245 from $225, roughly in line with the consensus analyst target.

Analysis

CAH’s move looks less like a fresh fundamental re-rate and more like a positioning unwind after a violent squeeze higher in a defensive sector. When a distributor breaks to new highs while healthcare leadership broadens, marginal buyers become less about valuation and more about benchmark-chasing, which is exactly when trims make sense: the next leg higher usually requires either an earnings beat or another macro scare, not just relative strength.

The second-order implication is that this strength is likely redistributive within healthcare rather than additive. If capital is rotating into the group, it may favor higher-beta pharma/biotech and services over low-volatility operators that have already normalized, which means CAH could underperform even if the sector stays bid. The raising of the target to the consensus area also signals that the market is now pricing a cleaner execution story, leaving less room for multiple expansion from here.

Risk is mostly a near-term air-pocket: after a 20% monthly run, any cool-off in the sector or a single miss on operating margin could compress the stock quickly because the move has likely pulled forward several months of good news. The contrarian view is that the market may still be underestimating the durability of distributor economics in a higher-utilization healthcare environment; if drug volumes and mix stay firm, CAH can grind higher even without further multiple expansion, but the risk/reward is now notably less attractive than it was two weeks ago.

Key Decisions for Investors

• Trim CAH into strength over the next 1-3 sessions; use any intraday move toward recent highs to reduce exposure, since upside from here appears capped unless earnings re-accelerate.
• If long healthcare exposure is desired, rotate from CAH into JNJ on weakness: JNJ offers a cleaner quality factor with less near-term multiple risk, while retaining defensive sector support over the next 1-3 months.
• Pair trade: long JNJ / short CAH for 4-8 weeks; thesis is that CAH has already priced the sector rotation, while JNJ still benefits from defensiveness without the same post-rally air-pocket risk.
• For aggressive accounts, sell CAH covered calls 1-2 months out around strikes near the new target zone; this monetizes elevated post-rally implied volatility while preserving most upside.
• Set a downside trigger on CAH below the prior breakout area; if it loses that level, expect a fast mean reversion as momentum buyers exit and consider re-adding only after consolidation.